NPDC by Mutation of NPC1 and NPC2: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Dongun Lee
,
Jeong Hee Hong

Cholesterol trafficking is initiated by the endocytic pathway and transported from endo/lysosomes to other intracellular organelles. Deficiencies in cholesterol-sensing and binding proteins NPC1 and NPC2 induce accumulation in lysosomes and the malfunction of trafficking to other organelles. Each organelle possesses regulatory factors to induce cholesterol trafficking. The mutation of NPC1 and NPC2 genes induces Niemann-Pick disease type C (NPDC), which is a hereditary disease and causes progressive neurodegeneration, developmental disability, hypotonia, and ataxia. Oxidative stress induces damage in NPDC-related intracellular organelles. Although studies on the relationship between NPDC and oxidation are relatively rare, several studies have reported the therapeutic potential of antioxidants in treating NPDC. Investigating antioxidant drugs to relieve oxidative stress and cholesterol accumulation is suggested to be a powerful tool for developing treatments for NPDC. Understanding NPDC provides challenging issues in understanding the oxidative stress–lysosome metabolism of the lipid axis.

  • cholesterol trafficking
  • Niemann-Pick disease type C
  • lysosomal storage disorders
  • lysosomal proteins
  • oxidative stress

1. Introduction

Niemann-Pick type C (NPC) is a lysosomal membrane-bound protein that maintains lipid homeostasis by mediating cholesterol trafficking from lysosomes [1]. The critical component of cellular membranes, cholesterol, has to be transported by binding proteins because cholesterol has hydrophobicity, which disturbs transportation through water [2].
Both NPC1 and NPC2 interact with cholesterol for transportation [3]. NPC1 is ubiquitously expressed, and cholesterol is transferred from NPC2 to NPC1 [4]. Structurally, NPC1 is a large glycoprotein containing a transmembrane domain and a sterol-sensing domain [5][6]. NPC1 is located on the transmembrane of lysosomes, while NPC2 is located in the lysosomal lumen to bind cholesterol [7], which is generated by the cholesteryl ester of low-density lipoprotein (LDL) hydrolysis in late endosomes and lysosomes [8][9]. NPC2-bound free cholesterol is transferred to the N-terminal domain of NPC1 for cholesterol transportation [10][11][12] (Figure 1).
Antioxidants 12 02021 g001
Figure 1. The protein structures of NPC1 and NPC2. The NPC1 has cholesterol/NPC2 binding sites in lysosomal lumen and sterol sensing domain/C terminal domain (CTD) in NPC1 transmembrane site. The NPC2 has signal peptides and cholesterol-binding domain.

2. The Relationship between NPDC and Lysosomes

2.1. Lysosomal Appearance and the Changes in Lysosomes in NPDC

Lysosomes are complicated intracellular organelles regulated by luminal pH, cellular nutrients, protein homeostasis, the transportation of ions, and pathogenic infections [13][14][15][16]. NPDC and cholesterol accumulation induce imbalances in cellular functions. To maintain the function of lysosomal membrane proteins, lysosomes must exist in intact forms to not cause membrane destabilization. NPC1 knock-out disrupted lysosomal morphology in a mice model, and increased lysosomal-associated membrane protein (LAMP)-1 was observed in NPDC mice and NPDC patients [17][18][19]. LAMP-1 is expressed in the lysosomal membrane to modulate lysosomal activity. Deficiencies in NPC1 not only increased LAMP-1 expression but also LAMP-1 glycosylation [20]. Glycosylation is an essential process for lysosomal membrane proteins for vesicle trafficking, and the abnormal glycosylation of LAMP-1 possesses the potential to induce NPDC [21]. LAMP-1 hyper-glycosylation was observed in the cerebellum of NPC1 knock-out mice [20]. In addition, lysosomal membrane stabilization is associated with ion transportation through the lysosomal membranes. The transportation of Ca2+ has been fully studied for lysosomal activation [22]. Glycyl-L-phenylalanine 2-naphthylamide (GPN, lysosomotropic agent, a drug that penetrates lysosomes)-induced lysosomal Ca2+ release was attenuated in an NPDC-mimicking cellular model using U18666a with a megakaryocyte cell line (MEG-01), as well as in bacterial-infected RAW 264.7 cells, which inhibited the expression of NPC1 [17][23]. Regardless of the lysosomal components, the activation of lysosomes is regulated by lysosomal positioning [24]. Lysosomal movement plays a role in degrading substrates by fusing with autophagosomes and delivering cargos such as cholesterol. However, cholesterol accumulation in NPDC blocks lysosomal positioning [25]. In lysosomal transportation of cholesterol to the ER, the phosphorylation of phosphatidylinositol (PI) through phosphatidylinositol 4 kinases (PI4Ks) is induced to synthesize phosphatidylinositol 4-phosphate (PtdIns4P), which is located on the lysosomal membrane [26]. The inhibition of NPC1 through U18666a recruited PtdIns4P and PI4K and accumulated PtdIns4P and PI4K in the lysosomal membrane to inhibit autophagy by activating rapamycin complex 1 (mTORC1), as described in Figure 2 [26]. Consequently, deficiency in NPC proteins modulates lysosomal proteins and positioning and subsequently blocks lysosomal cholesterol trafficking. 
Antioxidants 12 02021 g002
Figure 2. The effect of U18666a on PtdIns4P. The treatment of U18666a inhibits phosphorylation of PtdIns and induces activation of mTORC1 to inhibit cholesterol transport. NPC1: Niemann-Pick type C 1; PtdIns4P: phosphatidylinositol 4-phosphate; and PI4K: phosphatidylinositol 4 kinases.

2.2. The Effect of the Lysosomal Proteins on NPDC

Lysosomal membrane proteins have connections with ER membrane proteins to transfer cholesterol from lysosomes to the ER. The ER is associated with lysosomal membrane proteins, such as star-related lipid transfer domain-containing 3 (StARD3), ras-related protein rab-7, and oxysterol-binding protein homologue express [27]. In NPC1 mutant Chinese hamster ovary (CHO) cells, endolysosomal protein annexin A6 blocks ER-endolysosome connection by inhibiting StARD3 and rab-7 [28]. The knock-down of annexin A6 in NPC1 mutant CHO cells recovers cholesterol trafficking endolysosomes to ER [28]. In addition, the motor protein of lysosomes affects cholesterol transportation. For example, the biogenesis of lysosome-related organelle (BOLC) one-related complex (BORC) recruits ARL8 to bind the kinesin light chain/kinesin family member 5 complex, which binds microtubules to move lysosomes [29]. The knock-out of BORC and ARL8 caused cholesterol accumulation, which is indicated by an increase in the filipin intensity in HeLa cell lysosomes [30]. Disruption of the BORC/ARL8 complex induced the secretion of NPC2 from lysosomes [30]. Lysosomes have components that are physically involved in the transportation of cholesterol. The lysosomal proteins not only directly contact proteins but are involved in cholesterol transportation and NPDC-related reactions. Nutrient starvation is the classical stimulation of macroautophagy, which induces lysosomal activation by decreasing amino acid levels in lysosomes [31]. This starvation inhibits mammalian targets of mTORC1, which inhibits lysosomal binding to lysosomes [32]. mTORC1 inhibition induced nuclear translocation of the transcription factor EB (TFEB) to express lysosomal genes to activate lysosomes [32]. The knock-out of NPC1 induced mitochondrial damage and lysosomal membrane damage with the hyper-activation of mTORC1 in mouse embryonic fibroblasts [33]. The deletion of NPC1 disrupted mitochondria morphology and increased LAMP2 accumulation [33]. The inhibition of mTORC1 through the Torin1 mTORC1 inhibitor recovered mitochondrial function and lysosomal membranes [33]. The TFEB activator genistein stimulated nuclear translocation and autophagic flux to increase LC3 II expression in NPDC patient fibroblasts [34]. Treatment with genistein induced lysosomal exocytosis and decreased cytosolic cholesterol levels in NPC1 patient fibroblasts [34]. Additionally, the lysosomal Ca2+ channel two-pore channel 2 (TPC2) regulates cholesterol accumulation [35]. An agonist of TPC2 (TPC2-A1-P) decreased cholesterol levels with the exocytosis of lysosomes in the human fibroblasts of NPDC patients [35]. The treatment of TPC2-A1-P attenuated the intensity of filipin, the cholesterol-detecting dye, and the fusion of LAMP1 with the plasma membrane [35]. Thus, regulation of the lysosomal proteins has been suggested as a therapeutic strategy for NPDC. However, the activation of lysosomes against NPDC does not always reflect satisfied results. For example, treatment with Torin1, which recovers lysosomal membranes as described above, failed to decrease cholesterol accumulation in lysosomes [33].

3. Current Therapeutic Strategies for NPDC

Various approaches to treating NPDC have been studied, such as simply lowering cholesterol, alternatively using other LSD drugs, and manipulating NPDC-related genes [36]. Additionally, adeno-associated viral vectors, heat shock protein (HSP), synthetic high-density lipoprotein (sHDL), histone deacetylase inhibitors, and F-Bod protein2 (Fbxo2)-mediated lysophagy have been suggested as NPDC therapies [37][38][39][40][41]. Especially, sHDL showed high efficiency in reducing cholesterol with cellular safety in NPC1I1061T-mutated human fibroblasts [38]. Mechanistically, sHDL modulates cholesterol regulatory genes, including 3-hydroxy-3-methylglutaryl-CoA reductase, hydroxymethylglutary-CoA synthase, ATP binding cassette subfamily A1, and NPC1 [38]. Although numerous drugs have been introduced, antioxidant-related drugs and strategies have also been suggested for NPDC treatment. Thus, the researchers summarized the antioxidant-related drugs and non-antioxidant methods for NPDC treatment (Figure 3).
Antioxidants 12 02021 g003
Figure 3. The therapeutic strategies using antioxidants or non-antioxidants. The antioxidants-related NPDC treatment includes HSP70, miglustat, CoQ10, cyclodextrin, and NAC by decreasing oxidative stresses. The non-antioxidant-related NPDC treatment includes lysophagy, panovinostat, vorinostat, and adenovirus by supplementation of antioxidants. HSP70: heat shock protein 70; CoQ10: coenzyme Q10, NAC: N-acetylcysteine; FBXO2: F-Box protein 2.

3.1. Antioxidant-Related Drugs for NPDC Treatment

3.1.1. N-Butyl-Deoxynojirimycin (Miglustat)

As mentioned in the Introduction, oxidative stress is an outcome of NPDC. For example, thiobarbituric acid-reactive species (TBARS), the product of lipid peroxidation, was found to be increased, and the total antioxidant status (TAS) was decreased in the plasma of NPC patients [42]. Although the damaging effects of miglustat, the inhibitor of glycosphingolipid synthesis, on the neuronal system in NPDC patients have not been demonstrated, treatment with miglustat attenuated TBARS levels and recovered TAS levels in the serum of patients with NPDC [42].

3.1.2. N-Acetylcysteine and Coenzyme Q10

Antioxidants and antioxidation-related compounds, including N-acetylcysteine (NAC) and coenzyme Q10 (CoQ10), have therapeutic effects on NPDC [43]. The ROS scavenger NAC has been suggested as a clinical application to manage oxidative stress [44]. Treatment with NAC recovered liver pathology in NPDC mice [45]. NAC normalized liver weight, plasma levels of alanine aminotransferase (ALT)/aspartate aminotransferase (AST), and liver glutathione levels in NPDC mice [45]. CoQ10 is a component of the electron transport chain and acts as a lipophilic antioxidant [46]. Treatment with CoQ10 decreased cholesterol levels in NPDC patient dermal fibroblasts and cytokine levels in NPDC patient fibroblast-culture media [47].

3.1.3. Heat Shock Factor

Heat shock factors (HSFs) are metabolic proteins that induce protein folding, inhibit protein misfolding and aggregation, and prevent apoptosis [48][49] and oxidative stress [50]. For instance, heat shock protein 70 (HSP70) inhibited the activity of HSF, which induced the antioxidant reaction and reduced oxidative stress and ischemia/reperfusion injury [50][51]. HSP70 also recovered myelination in NPC knock-out mice [37][52]. In NPDC, myelin expression is defective because cholesterol is a component of myelination [53]. Thus, myelin defects are considered a marker of NPDC, and HSP70 is suggested for NPDC therapy.

3.1.4. Cyclodextrin

The β-cyclodextrin (CD) is the drug most frequently used for NPDC to decrease lysosomal cholesterol levels [54][55]. β-CD has been suggested as a secondary antioxidant, which enhances traditional antioxidants, such as resveratrol, pterostilbene, pinosylvin, oxyresveratrol, and astaxanthin [56], and β-CD shows antioxidant activity, although its efficacy is lower than that of traditional antioxidants [57]. Although the specific mechanisms of β-CD on lysosomes have not been demonstrated, derivatives of β-CD, such as 2-hydroxypropyl-β-CD (HP-β-CD) and 6-O-α-maltosyl-β-CD (Mal-β-CD), modulate lysosomes. HP-β-CD decreased lysosomal accumulation with decreases in lysosomal sphingolipid in NPC1-deleted CHO cells [58]. In HeLa cells, HP-β-CD induced endolysosomal secretion by activating transient receptor potential mucoplin-1 Ca2+ channels to reduce accumulated cholesterol [59]. Treatment with HP-β-CD induces lysosome-ER connections to trigger cholesterol trafficking [60]. In the same way, Mal-β-CD decreased the accumulation of lysosomes by reducing lysosomal expansion in NPC1-deficient CHO cells [61][62].

3.2. Non-Antioxidant Methods for NPDC Treatment

3.2.1. Lysophagy

Lysosomal membrane impairment induces oxidative stress [63][64]. Deletion of the Fbxo2 gene decreased lysophagy in mouse cortical neurons [40]. Fbxo2 treatment for NPDC decreased lipid-mediated lysosomal membrane damage [40]. These results suggest that oxidative stress is associated with cholesterol trafficking, and thus, lysophagy might help reduce cholesterol accumulation. Although non-antioxidant mechanisms are not the same as those of antioxidants, non-antioxidants effectively assist antioxidant-related drugs through synergistic effects with the development of endosomal and lysosomal trafficking.

3.2.2. Histone Deacetylase Inhibitors

The histone deacetylase inhibitors vorinostat and panobinostat recovered mutated NPC1I1061T localization [65]. NPC1I1061T mutation separated NPC1 from lysosomes, and treatment with vorinostat and panobinostat induced the movement of the NPC1 I1061T mutant type to lysosomes [65]. Although vorinostat and panobinostat are not antioxidants, the combination of these and antioxidants, such as vitamin C and naringenin, showed synergistic effects with vorinostat and panobinostat [66][67]. Antioxidant-related molecules, including β-CD, vorinostat, and panobinostat, have therapeutic potential for NPDC, but the relationship between these molecules and oxidation has not been fully demonstrated. The Food and Drug Administration (FDA) approved another histone deacetylase, valproic acid (VPA), to reduce cholesterol accumulation in NPDC patient-derived fibroblasts [39]. The combined administration of VPA with another CD-type of M-β-CD induced NPC1 trafficking from endosomes to the ER or Golgi in NPC1I1061T-mutated human fibroblasts [39], providing evidence of the synergistic effect with antioxidants of lysosomal trafficking.

3.2.3. Adenovirus

Adenovirus has been used as a gene delivery vector to easily penetrate cellular membranes and transfer to the nucleus [68][69]. The transduction of adenovirus cloning with NPC1 genes induced the stable expression of NPC1 proteins in NPC1 knock-out mice [70]. Injection with NPC1-inserted adenovirus increased the survival rate of Purkinje cells in NPC1 knock-out mice [71]. Recovery of Purkinje cells by adenovirus injection ameliorated impaired behavior and the survival rates of NPC1 knock-out mice [71]. Adenovirus early region 3 (RIDα) mimics the role of rab7 protein in the translocation of endosomes and lysosomes [72][73]. Rab7 interacts with lysosomal motor dynein and OSBP family ORP1L, which senses cholesterol levels in lysosomes for the translocation of lysosomes [74][75]. RIDα is substituted for rab7 in rab7-depleted cells to translocate cholesterol [72][73]. RIDα also induced the repositioning of lysosomal and autophagic vesicles to juxtanuclear regions to trigger autophagic flux and cholesterol trafficking in NPDC fibroblasts [76].

This entry is adapted from the peer-reviewed paper 10.3390/antiox12122021

References

  1. Vanier, M.T. Complex lipid trafficking in Niemann-Pick disease type C. J. Inherit. Metab. Dis. 2015, 38, 187–199.
  2. Li, X.; Wang, J.; Coutavas, E.; Shi, H.; Hao, Q.; Blobel, G. Structure of human Niemann-Pick C1 protein. Proc. Natl. Acad. Sci. USA 2016, 113, 8212–8217.
  3. Winkler, M.B.L.; Kidmose, R.T.; Szomek, M.; Thaysen, K.; Rawson, S.; Muench, S.P.; Wustner, D.; Pedersen, B.P. Structural Insight into Eukaryotic Sterol Transport through Niemann-Pick Type C Proteins. Cell 2019, 179, 485–497.
  4. Carstea, E.D.; Morris, J.A.; Coleman, K.G.; Loftus, S.K.; Zhang, D.; Cummings, C.; Gu, J.; Rosenfeld, M.A.; Pavan, W.J.; Krizman, D.B.; et al. Niemann-Pick C1 disease gene: Homology to mediators of cholesterol homeostasis. Science 1997, 277, 228–231.
  5. Kuwabara, P.E.; Labouesse, M. The sterol-sensing domain: Multiple families, a unique role? Trends Genet 2002, 18, 193–201.
  6. Goldstein, J.L.; DeBose-Boyd, R.A.; Brown, M.S. Protein sensors for membrane sterols. Cell 2006, 124, 35–46.
  7. Petersen, D.; Reinholdt, P.; Szomek, M.; Hansen, S.K.; Poongavanam, V.; Dupont, A.; Heegaard, C.W.; Krishnan, K.; Fujiwara, H.; Covey, D.F.; et al. Binding and intracellular transport of 25-hydroxycholesterol by Niemann-Pick C2 protein. Biochim. Biophys. Acta Biomembr. 2020, 1862, 183063.
  8. Brown, M.S.; Goldstein, J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232, 34–47.
  9. Roth, M.G. Clathrin-mediated endocytosis before fluorescent proteins. Nat. Rev. Mol. Cell Biol. 2006, 7, 63–68.
  10. Kwon, H.J.; Abi-Mosleh, L.; Wang, M.L.; Deisenhofer, J.; Goldstein, J.L.; Brown, M.S.; Infante, R.E. Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell 2009, 137, 1213–1224.
  11. Infante, R.E.; Abi-Mosleh, L.; Radhakrishnan, A.; Dale, J.D.; Brown, M.S.; Goldstein, J.L. Purified NPC1 protein. I. Binding of cholesterol and oxysterols to a 1278-amino acid membrane protein. J. Biol. Chem. 2008, 283, 1052–1063.
  12. Infante, R.E.; Radhakrishnan, A.; Abi-Mosleh, L.; Kinch, L.N.; Wang, M.L.; Grishin, N.V.; Goldstein, J.L.; Brown, M.S. Purified NPC1 protein: II. Localization of sterol binding to a 240-amino acid soluble luminal loop. J. Biol. Chem. 2008, 283, 1064–1075.
  13. Lee, D.; Hong, J.H. Nanoparticle-Mediated Therapeutic Application for Modulation of Lysosomal Ion Channels and Functions. Pharmaceutics 2020, 12, 217.
  14. Perera, R.M.; Zoncu, R. The Lysosome as a Regulatory Hub. Annu. Rev. Cell. Dev. Biol. 2016, 32, 223–253.
  15. Mrschtik, M.; Ryan, K.M. Lysosomal proteins in cell death and autophagy. FEBS J. 2015, 282, 1858–1870.
  16. Qi, X.; Man, S.M.; Malireddi, R.K.; Karki, R.; Lupfer, C.; Gurung, P.; Neale, G.; Guy, C.S.; Lamkanfi, M.; Kanneganti, T.D. Cathepsin B modulates lysosomal biogenesis and host defense against Francisella novicida infection. J. Exp. Med. 2016, 213, 2081–2097.
  17. Chen, O.C.W.; Colaco, A.; Davis, L.C.; Kiskin, F.N.; Farhat, N.Y.; Speak, A.O.; Smith, D.A.; Morris, L.; Eden, E.; Tynan, P.; et al. Defective platelet function in Niemann-Pick disease type C1. JIMD Rep. 2020, 56, 46–57.
  18. Grinan-Ferre, C.; Companys-Alemany, J.; Jarne-Ferrer, J.; Codony, S.; Gonzalez-Castillo, C.; Ortuno-Sahagun, D.; Vilageliu, L.; Grinberg, D.; Vazquez, S.; Pallas, M. Inhibition of Soluble Epoxide Hydrolase Ameliorates Phenotype and Cognitive Abilities in a Murine Model of Niemann Pick Type C Disease. Int. J. Mol. Sci. 2021, 22, 3409.
  19. Saito, R.; Miyajima, T.; Iwamoto, T.; Wu, C.; Suzuki, K.; Hossain, M.A.; Munakata, M.; Era, T.; Eto, Y. A neuropathological cell model derived from Niemann-Pick disease type C patient-specific iPSCs shows disruption of the p62/SQSTM1-KEAP1-NRF2 Axis and impaired formation of neuronal networks. Mol. Genet. Metab. Rep. 2021, 28, 100784.
  20. Cawley, N.X.; Lyons, A.T.; Abebe, D.; Luke, R.; Yerger, J.; Telese, R.; Wassif, C.A.; Bailey-Wilson, J.E.; Porter, F.D. Complex N-Linked Glycosylation: A Potential Modifier of Niemann-Pick Disease, Type C1 Pathology. Int. J. Mol. Sci. 2022, 23, 5082.
  21. Cawley, N.X.; Sojka, C.; Cougnoux, A.; Lyons, A.T.; Nicoli, E.R.; Wassif, C.A.; Porter, F.D. Abnormal LAMP1 glycosylation may play a role in Niemann-Pick disease, type C pathology. PLoS ONE 2020, 15, e0227829.
  22. Li, P.; Gu, M.X.; Xu, H.X. Lysosomal Ion Channels as Decoders of Cellular Signals. Trends Biochem. Sci. 2019, 44, 110–124.
  23. Fineran, P.; Lloyd-Evans, E.; Lack, N.A.; Platt, N.; Davis, L.C.; Morgan, A.J.; Hoglinger, D.; Tatituri, R.V.V.; Clark, S.; Williams, I.M.; et al. Pathogenic mycobacteria achieve cellular persistence by inhibiting the Niemann-Pick Type C disease cellular pathway. Wellcome Open Res. 2016, 1, 18.
  24. Pu, J.; Guardia, C.M.; Keren-Kaplan, T.; Bonifacino, J.S. Mechanisms and functions of lysosome positioning. J. Cell Sci. 2016, 129, 4329–4339.
  25. Roney, J.C.; Li, S.; Farfel-Becker, T.; Huang, N.; Sun, T.; Xie, Y.; Cheng, X.T.; Lin, M.Y.; Platt, F.M.; Sheng, Z.H. Lipid-mediated impairment of axonal lysosome transport contributing to autophagic stress. Autophagy 2021, 17, 1796–1798.
  26. Lim, C.Y.; Davis, O.B.; Shin, H.R.; Zhang, J.; Berdan, C.A.; Jiang, X.; Counihan, J.L.; Ory, D.S.; Nomura, D.K.; Zoncu, R. ER-lysosome contacts enable cholesterol sensing by mTORC1 and drive aberrant growth signalling in Niemann-Pick type C. Nat. Cell Biol. 2019, 21, 1206–1218.
  27. Nguyen, M.K.L.; Jose, J.; Wahba, M.; Bernaus-Esque, M.; Hoy, A.J.; Enrich, C.; Rentero, C.; Grewal, T. Linking Late Endosomal Cholesterol with Cancer Progression and Anticancer Drug Resistance. Int. J. Mol. Sci. 2022, 23, 7206.
  28. Meneses-Salas, E.; Garcia-Melero, A.; Kanerva, K.; Blanco-Munoz, P.; Morales-Paytuvi, F.; Bonjoch, J.; Casas, J.; Egert, A.; Beevi, S.S.; Jose, J.; et al. Annexin A6 modulates TBC1D15/Rab7/StARD3 axis to control endosomal cholesterol export in NPC1 cells. Cell Mol. Life Sci. 2020, 77, 2839–2857.
  29. Guardia, C.M.; Farias, G.G.; Jia, R.; Pu, J.; Bonifacino, J.S. BORC Functions Upstream of Kinesins 1 and 3 to Coordinate Regional Movement of Lysosomes along Different Microtubule Tracks. Cell Rep. 2016, 17, 1950–1961.
  30. Anderson, J.; Walker, G.; Pu, J. BORC-ARL8-HOPS ensemble is required for lysosomal cholesterol egress through NPC2. Mol. Biol. Cell 2022, 33, ar81.
  31. Kristensen, A.R.; Schandorff, S.; Hoyer-Hansen, M.; Nielsen, M.O.; Jaattela, M.; Dengjel, J.; Andersen, J.S. Ordered Organelle Degradation during Starvation-induced Autophagy. Mol. Cell. Proteom. 2008, 7, 2419–2428.
  32. Settembre, C.; Ballabio, A. Lysosomal Adaptation: How the Lysosome Responds to External Cues. Csh Perspect. Biol. 2014, 6, a016907.
  33. Davis, O.B.; Shin, H.R.; Lim, C.Y.; Wu, E.Y.; Kukurugya, M.; Maher, C.F.; Perera, R.M.; Ordonez, M.P.; Zoncu, R. NPC1-mTORC1 Signaling Couples Cholesterol Sensing to Organelle Homeostasis and Is a Targetable Pathway in Niemann-Pick Type C. Dev. Cell 2021, 56, 260–276.e7.
  34. Arguello, G.; Balboa, E.; Tapia, P.J.; Castro, J.; Yanez, M.J.; Mattar, P.; Pulgar, R.; Zanlungo, S. Genistein Activates Transcription Factor EB and Corrects Niemann-Pick C Phenotype. Int. J. Mol. Sci. 2021, 22, 4220.
  35. Rosato, A.S.; Krogsaeter, E.K.; Jaslan, D.; Abrahamian, C.; Montefusco, S.; Soldati, C.; Spix, B.; Pizzo, M.T.; Grieco, G.; Bock, J.; et al. TPC2 rescues lysosomal storage in mucolipidosis type IV, Niemann-Pick type C1, and Batten disease. Embo Mol. Med. 2022, 14, e15377.
  36. Sitarska, D.; Tylki-Szymanska, A.; Lugowska, A. Treatment trials in Niemann-Pick type C disease. Metab. Brain Dis. 2021, 36, 2215–2221.
  37. Kirkegaard, T.; Gray, J.; Priestman, D.A.; Wallom, K.L.; Atkins, J.; Olsen, O.D.; Klein, A.; Drndarski, S.; Petersen, N.H.T.; Ingemann, L.; et al. Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses. Sci. Transl. Med. 2016, 8, 355ra118.
  38. Schultz, M.L.; Fawaz, M.V.; Azaria, R.D.; Hollon, T.C.; Liu, E.A.; Kunkel, T.J.; Halseth, T.A.; Krus, K.L.; Ming, R.; Morin, E.E.; et al. Synthetic high-density lipoprotein nanoparticles for the treatment of Niemann-Pick diseases. BMC Med. 2019, 17, 200.
  39. Subramanian, K.; Hutt, D.M.; Scott, S.M.; Gupta, V.; Mao, S.; Balch, W.E. Correction of Niemann-Pick type C1 trafficking and activity with the histone deacetylase inhibitor valproic acid. J. Biol. Chem. 2020, 295, 8017–8035.
  40. Liu, E.A.; Schultz, M.L.; Mochida, C.; Chung, C.; Paulson, H.L.; Lieberman, A.P. Fbxo2 mediates clearance of damaged lysosomes and modifies neurodegeneration in the Niemann-Pick C brain. JCI Insight 2020, 5, e136676.
  41. Carlin, C.; Manor, D. Adenovirus Reveals New Pathway for Cholesterol Egress from the Endolysosomal System. Int. J. Mol. Sci. 2020, 21, 5808.
  42. Ribas, G.S.; Pires, R.; Coelho, J.C.; Rodrigues, D.; Mescka, C.P.; Vanzin, C.S.; Biancini, G.B.; Negretto, G.; Wayhs, C.A.; Wajner, M.; et al. Oxidative stress in Niemann-Pick type C patients: A protective role of N-butyl-deoxynojirimycin therapy. Int. J. Dev. Neurosci. 2012, 30, 439–444.
  43. Hammerschmidt, T.G.; Guerreiro, G.B.; Donida, B.; Raabe, M.; Kessler, R.G.; Ferro, M.B.; Moura, D.J.; Giugliani, R.; Vargas, C.R. Beneficial in vitro effect of N-acetylcysteine and coenzyme Q10 on DNA damage in neurodegenerative Niemann-Pick type C 1 disease: Preliminary results. Naunyn Schmiedebergs Arch. Pharmacol. 2023, 396, 1563–1569.
  44. Millea, P.J. N-acetylcysteine: Multiple clinical applications. Am. Fam. Physician 2009, 80, 265–269.
  45. Fu, R.; Wassif, C.A.; Yanjanin, N.M.; Watkins-Chow, D.E.; Baxter, L.L.; Incao, A.; Liscum, L.; Sidhu, R.; Firnkes, S.; Graham, M.; et al. Efficacy of N-acetylcysteine in phenotypic suppression of mouse models of Niemann-Pick disease, type C1. Hum. Mol. Genet 2013, 22, 3508–3523.
  46. Hargreaves, I.P. Ubiquinone: Cholesterol’s reclusive cousin. Ann. Clin. Biochem. 2003, 40, 207–218.
  47. Hammerschmidt, T.G.; Donida, B.; Faverzani, J.L.; Moura, A.P.; Dos Reis, B.G.; Machado, A.Z.; Kessler, R.G.; Sebastiao, F.M.; Reinhardt, L.S.; Moura, D.J.; et al. Cytokine profile and cholesterol levels in patients with Niemann-Pick type C disease presenting neurological symptoms: In vivo effect of miglustat and in vitro effect of N-acetylcysteine and coenzyme Q10. Exp. Cell Res. 2022, 416, 113175.
  48. Verghese, J.; Abrams, J.; Wang, Y.; Morano, K.A. Biology of the heat shock response and protein chaperones: Budding yeast (Saccharomyces cerevisiae) as a model system. Microbiol. Mol. Biol. Rev. 2012, 76, 115–158.
  49. Hightower, L.E. Heat shock, stress proteins, chaperones, and proteotoxicity. Cell 1991, 66, 191–197.
  50. Szyller, J.; Bil-Lula, I. Heat Shock Proteins in Oxidative Stress and Ischemia/Reperfusion Injury and Benefits from Physical Exercises: A Review to the Current Knowledge. Oxid. Med. Cell. Longev. 2021, 2021, 6678457.
  51. Shi, Y.; Mosser, D.D.; Morimoto, R.I. Molecular chaperones as HSF1-specific transcriptional repressors. Genes Dev. 1998, 12, 654–666.
  52. Gray, J.; Fernandez-Suarez, M.E.; Falah, M.; Smith, D.; Smith, C.; Kaya, E.; Palmer, A.M.; Fog, C.K.; Kirkegaard, T.; Platt, F.M. Heat shock protein amplification improves cerebellar myelination in the Npc1(nih) mouse model. EBioMedicine 2022, 86, 104374.
  53. Bernardo, A.; De Nuccio, C.; Visentin, S.; Martire, A.; Minghetti, L.; Popoli, P.; Ferrante, A. Myelin Defects in Niemann-Pick Type C Disease: Mechanisms and Possible Therapeutic Perspectives. Int. J. Mol. Sci. 2021, 22, 8858.
  54. Feltes, M.; Gale, S.E.; Moores, S.; Ory, D.S.; Schaffer, J.E. Monitoring the itinerary of lysosomal cholesterol in Niemann-Pick Type C1-deficient cells after cyclodextrin treatment. J. Lipid Res. 2020, 61, 403–412.
  55. Donida, B.; Raabe, M.; Tauffner, B.; de Farias, M.A.; Machado, A.Z.; Timm, F.; Kessler, R.G.; Hammerschmidt, T.G.; Reinhardt, L.S.; Brito, V.B.; et al. Nanoparticles containing beta-cyclodextrin potentially useful for the treatment of Niemann-Pick C. J. Inherit. Metab. Dis. 2020, 43, 586–601.
  56. Lopez-Nicolas, J.M.; Rodriguez-Bonilla, P.; Garcia-Carmona, F. Cyclodextrins and antioxidants. Crit. Rev. Food Sci. Nutr. 2014, 54, 251–276.
  57. Jo, Y.J.; Cho, H.S.; Chun, J.Y. Antioxidant activity of beta-cyclodextrin inclusion complexes containing trans-cinnamaldehyde by DPPH, ABTS and FRAP. Food Sci. Biotechnol. 2021, 30, 807–814.
  58. Hoque, S.; Kondo, Y.; Sakata, N.; Yamada, Y.; Fukaura, M.; Higashi, T.; Motoyama, K.; Arima, H.; Higaki, K.; Hayashi, A.; et al. Differential Effects of 2-Hydroxypropyl-Cyclodextrins on Lipid Accumulation in Npc1-Null Cells. Int. J. Mol. Sci. 2020, 21, 898.
  59. Vacca, F.; Vossio, S.; Mercier, V.; Moreau, D.; Johnson, S.; Scott, C.C.; Montoya, J.P.; Moniatte, M.; Gruenberg, J. Cyclodextrin triggers MCOLN1-dependent endo-lysosome secretion in Niemann-Pick type C cells. J. Lipid Res. 2019, 60, 832–843.
  60. Singhal, A.; Krystofiak, E.S.; Jerome, W.G.; Song, B. 2-Hydroxypropyl-gamma-cyclodextrin overcomes NPC1 deficiency by enhancing lysosome-ER association and autophagy. Sci. Rep. 2020, 10, 8663.
  61. Okada, Y.; Kuroiwa, S.; Noi, A.; Tanaka, A.; Nishikawa, J.; Kondo, Y.; Ishitsuka, Y.; Irie, T.; Higaki, K.; Matsuo, M.; et al. Effects of 6-O-a-maltosyl-S cyclodextrin on lipid metabolism in Npc1-deficient Chinese hamster ovary cells. Mol. Genet. Metab. 2022, 137, 239–248.
  62. Yasmin, N.; Ishitsuka, Y.; Fukaura, M.; Yamada, Y.; Nakahara, S.; Ishii, A.; Kondo, Y.; Takeo, T.; Nakagata, N.; Motoyama, K.; et al. In Vitro and In Vivo Evaluation of 6-O-Maltosyl-Cyclodextrin as a Potential Therapeutic Agent against Niemann-Pick Disease Type C. Int. J. Mol. Sci. 2019, 20, 1152.
  63. Mizushima, N. The ubiquitin E2 enzyme UBE2QL1 mediates lysophagy. EMBO Rep. 2019, 20, e49104.
  64. Papadopoulos, C.; Kravic, B.; Meyer, H. Repair or Lysophagy: Dealing with Damaged Lysosomes. J. Mol. Biol. 2020, 432, 231–239.
  65. Pipalia, N.H.; Subramanian, K.; Mao, S.; Ralph, H.; Hutt, D.M.; Scott, S.M.; Balch, W.E.; Maxfield, F.R. Histone deacetylase inhibitors correct the cholesterol storage defect in most Niemann-Pick C1 mutant cells. J. Lipid Res. 2017, 58, 695–708.
  66. Cardoso, B.A.; Ramos, T.L.; Belo, H.; Vilas-Boas, F.; Real, C.; Almeida, A.M. Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms. Exp. Hematol. 2019, 72, 60–71.e11.
  67. Moshref, M.; Questa, M.; Lopez-Cervantes, V.; Sears, T.K.; Greathouse, R.L.; Crawford, C.K.; Kol, A. Panobinostat Effectively Increases Histone Acetylation and Alters Chromatin Accessibility Landscape in Canine Embryonic Fibroblasts but Does Not Enhance Cellular Reprogramming. Front. Vet. Sci. 2021, 8, 716570.
  68. Luisoni, S.; Suomalainen, M.; Boucke, K.; Tanner, L.B.; Wenk, M.R.; Guan, X.L.; Grzybek, M.; Coskun, U.; Greber, U.F. Co-option of Membrane Wounding Enables Virus Penetration into Cells. Cell Host Microbe 2015, 18, 75–85.
  69. Suomalainen, M.; Nakano, M.Y.; Boucke, K.; Keller, S.; Greber, U.F. Adenovirus-activated PKA and p38/MAPK pathways boost microtubule-mediated nuclear targeting of virus. Embo J. 2001, 20, 1310–1319.
  70. Paul, C.A.; Reid, P.C.; Boegle, A.K.; Karten, B.; Zhang, M.; Jiang, Z.G.; Franz, D.; Lin, L.; Chang, T.Y.; Vance, J.E.; et al. Adenovirus expressing an NPC1-GFP fusion gene corrects neuronal and nonneuronal defects associated with Niemann pick type C disease. J. Neurosci. Res. 2005, 81, 706–719.
  71. Xie, C.; Gong, X.M.; Luo, J.; Li, B.L.; Song, B.L. AAV9-NPC1 significantly ameliorates Purkinje cell death and behavioral abnormalities in mouse NPC disease. J. Lipid Res. 2017, 58, 512–518.
  72. Zeng, X.; Carlin, C.R. Adenovirus early region 3 RIDalpha protein limits NFkappaB signaling through stress-activated EGF receptors. PLoS Pathog. 2019, 15, e1008017.
  73. Shah, A.H.; Cianciola, N.L.; Mills, J.L.; Sonnichsen, F.D.; Carlin, C. Adenovirus RIDalpha regulates endosome maturation by mimicking GTP-Rab7. J. Cell Biol. 2007, 179, 965–980.
  74. Rocha, N.; Kuijl, C.; van der Kant, R.; Janssen, L.; Houben, D.; Janssen, H.; Zwart, W.; Neefjes, J. Cholesterol sensor ORP1L contacts the ER protein VAP to control Rab7-RILP-p150 Glued and late endosome positioning. J. Cell Biol. 2009, 185, 1209–1225.
  75. Johansson, M.; Rocha, N.; Zwart, W.; Jordens, I.; Janssen, L.; Kuijl, C.; Olkkonen, V.M.; Neefjes, J. Activation of endosomal dynein motors by stepwise assembly of Rab7-RILP-p150Glued, ORP1L, and the receptor betalll spectrin. J. Cell Biol. 2007, 176, 459–471.
  76. Cianciola, N.L.; Carlin, C.R. Adenovirus RID-alpha activates an autonomous cholesterol regulatory mechanism that rescues defects linked to Niemann-Pick disease type C. J. Cell Biol. 2009, 187, 537–552.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback